Gossamer Bio to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in December.

Piper Sandler 37th Annual Healthcare Conference

Oppenheimer Movers in Rare Disease Summit

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251124688603/en/

For Investors and Media
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
[email protected]

Source: Gossamer Bio, Inc.

You May Also Be Interested In

• Kevin Jones named President of Deluxe Merchant Services
• IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
• Andersen Announces Launch of Secondary Offering